Ovid Therapeutics Inc - OVID Accounting Capitalization

Official company branding of Ovid Rx (OVID)

The price history of Ovid Therapeutics Inc. (OVID) on the GURU.Markets platform is currently at 0.21. Ovid Therapeutics Inc. (OVID) minimizes environmental impact through energy efficiency and waste purification in its laboratories. The business relies on the development of unique enzyme preparations for the treatment of epilepsy, establishing a closed network of loyal patients. Meanwhile, the development of American science remains stable, as the humanitarian status of medicine precludes the influence of trade conflicts.

OVID: Ovid Rx Book Capitalization 07/04/2022 - 10/29/2026

OVID (Ovid Rx): analytical breakdowns and indicator data

- market price and analyst price targets:
Market Chart Ovid Therapeutics Inc.|OVID - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Ovid Therapeutics Inc|OVID - Total Company Value
- book capitalization indicators:
Equity per Share Ovid Therapeutics|OVID - Book Capitalization|Market-to-Book Ratio ovidrx.com|OVID - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Ovid Therapeutics Inc.|OVID - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Ovid Therapeutics Inc.|OVID - Company Debts|Debts to Book Value Ovid Therapeutics Inc|OVID - Company Long-Term Debt|Short-Term Debt Ovid Therapeutics|Quick Liquidity ovidrx.com
- earnings and valuation multiples information:
OVID - Net Profit
Initial company analysis:OVID, Ovid Therapeutics
Mass-produced product of ovidrx.com

The development of Ovid Therapeutics Inc. (OVID) depends on the success of clinical phases and partnership payments, which directly impact the volume of equity on the balance sheet. This metric, representing the sum of net assets minus liabilities, determines the real financial stability and the pace of business recovery. A local decline in this indicator may signal risks, whereas its growth confirms the reliability of capitalization.

Competitor analysis

Book Valuation of Business Biogen Idec BIIB|NBIX: Book Capitalization|Accounting Capitalization RGC|Company Book Value Axsome Therapeutics, Inc.|Accounting Capitalization ACAD (ACADIA Pharma)|Book Capitalization XENE|VKTX - Total Stockholders' Equity|Supernus Pharmaceuticals - Company Net Assets|Book Capitalization catalystpharma.com CPRX|DNLI - Company Book Value|Accounting Value of Company HRMY (Harmony Biosciences Inc)|Biohaven Pharmaceutical (BHVN) - Company Book Value|Total Stockholders' Equity Amylyx Corp (AMLX)|Company Book Value Trevi Therapeutics|Total Stockholders' Equity praxismedicines.com PRAX|Company Net Assets AVXL (Anavex Life Sciences Corp.)|Company Book Value CBLL (CeriBell Inc)|Book Capitalization PRTA (prothena.com)|Book Valuation of Business Alector Inc. (ALEC)|Annexon, Inc. - Book Capitalization|OMER (Omeros Corporation) - Accounting Capitalization|NGNE (Neurogene) - Company Net Assets|AC Immune S.A. - Accounting Value of Company|Company Net Assets VYGR|NMRA (Neumora Corp) - Total Net Assets|Book Capitalization SCLX|TVGN (tevogen.com) - Accounting Value of Company|Book Capitalization ACOG (Alpha Cognition Inc.)|cogrx.com (CGTX) - Total Stockholders' Equity|IKT - Company Book Value|Accounting Value of Company SAVA (Cassava Pharma)|ASRT: Book Capitalization|Coya Therapeutics (COYA) - Book Capitalization|Company Book Value VistaGen Therapeutics, Inc.|Acumen Pharmaceuticals Inc. - Net Asset Value|Book Capitalization CRVO|ATHE - Total Stockholders' Equity|Clene - Company Net Assets|Book Capitalization PepGen Inc PEPG|JUNS: Company Net Assets|Relmada Therapeutics Inc - Total Net Assets|ANVS: Book Capitalization|GRCE - Book Valuation of Business|AIFF (Firefly Neuroscience, Inc) - Book Capitalization|Company Net Assets ANEW Medical, Inc. (KLTO)|Company Book Value NeuroSense Therapeutics (NRSN)|Book Valuation of Business Reviva Pharmaceuticals Holdings Inc.|MetaVia - Company Net Assets|Accounting Value of Company NRXS|Helius Medical Technologies Inc. - Book Capitalization|Book Valuation of Business Passage Bio, Inc. PASG|bionomics.com.au (NEUP) - Company Book Value|Accounting Capitalization NERV|ATHA (Athira) - Book Capitalization|Company Net Assets Addex (ADXN)|Company Net Assets ALZN (Alzamend Neuro, Inc.)|Book Valuation of Business cyclerion.com|Company Book Value Protagenic Therapeutics, Inc. PTIX|Pasithea Therapeutics Corp (KTTA) - Total Stockholders' Equity|CRGT: Company Net Assets|ATXI: Company Book Value|BCLI: Book Capitalization|CARA - Book Valuation of Business|CHRO (Chromocell Therapeutics Corp.) - Book Capitalization|Accounting Capitalization ELYM (Eliem)|Company Book Value Intra-Cellular Therapies (ITCI)|Longboard - Accounting Capitalization|Book Capitalization MRNS (Marinus Pharmaceuticals)|nkgenbiotech.com (NKGN) - Total Stockholders' Equity|NRBO: Company Net Assets|SAGE - Book Capitalization|Neurotrope (SNPX) - Company Book Value|Trevena Inc - Accounting Value of Company|Company Book Value Vigil Neuroscience Inc.|Total Stockholders' Equity Anew Medical Inc. WENA|Company Book Value Cerevel Therapeutics, Inc. (CERE)